Zürich Metropolitan Area
Strategic, scientifically driven Medical Affairs leader with 13+ years’ experience shaping global and regional medical strategy, evidence generation and launches across rare, immunology, dermatology and cardiometabolic diseases. Proven partner to Clinical Development, providing strategic medical insights from early phase 1/2 through pivotal phase 3 and launch, with a strong record in cross-functional leadership, KOL engagement and integrated evidence planning that turns science into measurable business and patient impact.
Leading medical strategy for BridgeBio’s Skeletal Dysplasia portfolio across Europe, translating innovative rare disease science into impactful medical initiatives that support product launches and improve patient outcomes. Serving as a strategic scientific partner to cross-functional teams, healthcare professionals, patient organizations, and other key stakeholders, with a focus on advancing care for patients with rare skeletal disorders. Leveraging extensive regional rare disease expertise to drive scientific engagement, evidence generation and medical excellence.
Driving Novo Nordisk’s global obesity strategy across International Operations (IO), spanning all markets outside the U.S. • Leading the execution of medical strategy and tactics for obesity across IO, in close alignment with global medical and development priorities. • Advocating for recognition of obesity as a serious, chronic disease while connecting insights across the broader cardiometabolic portfolio. • Collaborating with regional and affiliate Medical Affairs teams to strengthen medical education, scientific exchange, and patient journey insights. • Bringing regional and market perspectives into global forums to inform clinical development and communication strategies. • Building high-impact scientific partnerships with thought leaders, academic institutions, and professional societies to elevate the global conversation on obesity.
Global Medical Affairs Launch Lead - Led the Global Medical Affairs team, accountable for shaping and executing global medical strategy to support successful development, launch, and life-cycle management of Concizumab (Alhemo). - Served as Medical Lead in the Global Development team (R&D, regulatory, clinical) within the matrix organisation - ensuring scientific and strategic alignment across functions. - Led the development and execution of the Global Medical Brand & Integrated Evidence Plan, collaborating with cross-functional teams (Marketing, Market Access, Corporate Affairs) to generate evidence that strengthened clinical differentiation and supported the product's value proposition. - Guided regional and focus markets medical teams in global (pre-)launch activities, driving excellence through Scientific Dialogue frameworks and OCE implementation, and empowering over 100 cross-functional ambassadors with targeted training. - Led global scientific communication and publication strategy, achieving high visibility and credibility through late-breaking abstracts at ISTH 2022/2023 and landmark Phase 3 publications in NEJM (2023) and The Lancet Haematology (2024), significantly enhancing the product's scientific reputation. - Chaired global advisory boards, translating actionable insights into LCM, RWE strategies, and future study designs, driving informed decision-making. - Accelerated Phase 3 study recruitment by implementing a novel collaboration model between Medical Affairs and Clinical Operations, improving recruitment timelines across global, regional, and country teams. - Contributed to clinical study design, regulatory submissions, and label negotiations, ensuring alignment with global regulatory and payer requirements (e.g. NICE, HAS, IQWiG), facilitating timely market access. - Built and maintained long-term relationships with global KOLs, medical societies, and external stakeholders, driving advocacy and elevating the scientific reputation of Concizumab.
1-year short-term assignment in Medical & Marketing, Cardiovascular Disease (CVD), International Operations & Strategy (IO–SO) • Spearheaded educational initiatives in the cardiovascular disease sector to enhance market entry strategies. • Led cross-functional project teams, collaborating with global and regional medical affairs leads. • Developed the “InFlame” webinar series and a comprehensive playbook for effective knowledge dissemination. • Organized a two-day preceptorship in collaboration with UK-Aachen, Germany, to enhance medical knowledge among healthcare professionals.
Therapeutic area: Rare Bleeding Disorders (Haemophilia, in-line and pipeline) • Developed and executed regional strategies for Haemophilia as part of a cross-functional team. • Co-led promotional and non-promotional meetings and symposia to enhance awareness and education. • Initiated a monthly Journal Club to foster scientific exchange among affiliates. • Served as the medical lead for the regional rollout of Haemoassist®, a medical eDiary device.
Rare Disease Lead Switzerland: Rare endocrine disorders, Rare non-malignant Haematology, Transplant, Amyloidosis, and Dermatology/Psoriasis • Led cross-functional project team to ensure the successful supply of Tafamidis for patients with the ultra-rare disease ATTR-Amyloidosis. • Planned and executed workshops and advisory boards to enhance stakeholder engagement and knowledge sharing. • Fostered strong relationships with Swiss patient organization and medical society to advocate for patient needs.
Therapeutic areas: Autoimmune/Immunology/Rheumatology & Dermatology • Led the medical affairs launch of Benlysta, a therapeutic antibody for systemic lupus erythematosus (SLE). • Integrated Toctino, a systemic dermatological therapy, into the product portfolio. • Planned and executed symposia, workshops, and advisory boards to enhance stakeholder engagement. • Conducted regulatory authority submissions and correspondence to ensure compliance and facilitate approvals.
EMBO Long-term Research Fellow conducted impactful research in diabetes and obesity • Collaborated with academic institutions and industry partners to enhance research outcomes. • Mentored PhD and Master students, fostering the next generation of researchers. • Developed training programs for technicians to effectively support research initiatives.